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Key Points 
 
1. Spontaneously regressed tumors are composed of a formerly proliferating CLL clone 
that has transitioned into a quiescent state. 
 
2. A change in microenvironmental stimulation on an indolent genomic background 
state underpins clonal attrition in spontaneous CLL regression.  
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Abstract 
Spontaneous regression is a recognized phenomenon in chronic lymphocytic 
leukemia (CLL) but its biological basis remains unknown. We undertook a detailed 
investigation of the biological and clinical features of 20 spontaneous CLL regression cases 
incorporating phenotypic, functional, transcriptomic and genomic studies at sequential 
timepoints. All spontaneously regressed tumors were IGHV-mutated with no restricted IGHV 
usage or B-cell receptor (BCR) stereotypy. They exhibited shortened telomeres similar to 
non-regressing CLL indicating prior proliferation. They also displayed low Ki-67, CD49d, 
sIgM expression and IgM signaling response but high CXCR4 expression indicating low 
proliferative activity associated with poor migration to proliferation centers, with these 
features becoming increasingly marked during regression. Spontaneously regressed CLL 
displayed a transcriptome profile characterized by downregulation of metabolic processes as 
well as MYC and its downstream targets compared to non-regressing CLL. Moreover, 
spontaneous regression was associated with reversal of T-cell exhaustion features including 
reduced PD-1 expression and increased T-cell proliferation. Interestingly, archetypal CLL 
genomic aberrations including HIST1H1B and TP53 mutations and del(13q14) were found in 
some spontaneously regressing tumors, but genetic composition remained stable during 
regression. Conversely, a single case of CLL relapse following spontaneous regression was 
associated with increased BCR signaling, CLL proliferation and clonal evolution. These 
observations indicate that spontaneously regressing CLL appear to undergo a period of 
proliferation before entering a more quiescent state, and that a complex interaction between 
genomic alterations and microenvironment determines disease course. Together, the 
findings provide novel insight into the biological processes underpinning spontaneous CLL 
regression, with implications for CLL treatment. 
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Introduction 
Spontaneous tumor regression, manifested by a sustained reduction or 
disappearance of the malignant clone without treatment, is an uncommon but intriguing 
phenomenon.1-6 In CLL, spontaneous disease regression is estimated to occur in 1-2% of 
patients,7,8 although CLL cells do remain at a low level despite the resolution of clinical 
features.7-9 Several case reports of spontaneous CLL regression have been published,9-11 as 
well as 2 case series which together describe a total of 19 cases.7,8 
Spontaneous tumor regression has been linked in some cases to infection, blood 
transfusion or secondary malignancy, and it has been suggested that these may reflect 
induction of a pro-inflammatory state.2,11 However, these associations are uncommon and as 
such the etiology of spontaneous regression is unclear. A study of 9 cases of spontaneously 
regressing CLL showed that tumors lacked CD38 and ZAP-70 expression and all 7 cases 
that underwent IGHV sequencing revealed an IGHV-mutated genotype with IGHV3 usage in 
6 of these.8 
Improved understanding of the biological basis underlying spontaneous CLL 
regression is important for elucidating CLL pathobiology and could help to inform therapeutic 
management. Multiple lines of evidence now suggest that the clinical outcomes for patients 
with CLL is shaped both by the biological properties of the malignant clone and its interaction 
with the microenvironment.12 Disease progression is often accompanied by increased CLL 
migration to proliferation centers with resultant BCR engagement and clonal proliferation.13-15 
Moreover, the emergence of mutations and genomic complexity may result in the outgrowth 
of CLL cells with greater proliferative and survival advantage.16-18 These changes, facilitated 
by impaired tumor immunity and a microenvironment conducive to CLL proliferation and 
apoptotic evasion,19-23 may shift the balance of CLL turnover in favor of clonal expansion. As 
such we postulated that spontaneous CLL regression may reflect the integration of a range 
of processes including BCR signaling and proliferation, apoptosis, genetic heterogeneity and 
host immunity. 
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To evaluate this hypothesis, we analyzed sequential samples from 20 patients who 
had undergone spontaneous CLL regression. Our analysis revealed unique features 
providing insight into the biology of this phenomenon. 
 
Patients, Material and Methods 
Patient samples 
We reviewed all 1425 patients with untreated CLL who attended 4 United Kingdom 
hemato-oncology centers between 2010 and 2016. We identified complete spontaneous 
CLL regression on the basis of a sustained reduction in absolute lymphocyte count (ALC) to 
below 4 x 109/L with complete resolution of CLL-related symptoms, anemia, 
thrombocytopenia and clinically detectable adenopathy. Identification of partial spontaneous 
regression was based on sustained reduction of lymphocytosis by ≥50% from the highest 
level, with regressing nodal disease. We excluded subjects with concurrent infections or 
second malignancies, or who were receiving myelosuppressive or immunosuppressive 
therapies, including systemic corticosteroids, for any indication immediately preceding or 
coinciding with the onset of CLL regression. In two individuals the onset of CLL regression 
predated the diagnosis of a second malignancy by ≤5 years (CLL18–19), which could impact 
on immune responses contributing to CLL regression. However, upon subsequent analysis 
no distinctive features were apparent between these two and other patients, thus, they were 
incorporated with the rest of the cohort. 
For comparison, CLL-treatment naïve, Binet stage-, age-, and sex-matched indolent 
CLL, along with age-, sex-matched progressive CLL and healthy controls were obtained. 
Indolent cases were further CMV-status matched for T-cell studies. To reflect real-life CLL 
populations, the groups were not matched for IGHV mutational status. However, subgroup 
analysis excluding the IGHV unmutated indolent cases did not affect the results. Indolent 
disease and healthy controls were recruited locally, while progressive samples were sourced 
from multicenter trials and obtained immediately before treatment (supplemental Table 1). 
Indolent CLL was defined as Binet stage A disease with a ≥2 year lymphocyte doubling time 
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monitored over ≥5 years. Samples were obtained with written patient consent and 
institutional ethical approval. 
 
Cell separation 
CLL cells (>95% CD19+ CD5+ cells; supplemental Table 2), for all non-FACS based 
assays, were isolated using a MACS procedure (Miltenyi Biotec, Surrey, UK), as detailed in 
supplemental methods. 
 
Flow cytometry 
Extracellular and intracellular staining procedures are detailed in supplemental 
methods and supplemental Table 3. 
 
Nucleic acid extraction 
Telomere length, genomic and transcriptomic studies were performed on DNA and 
mRNA extracted from isolated CLL cells. 
 
Telomere length, telomerase and replicative senescence assays 
XpYp chromosome-specific single telomere length analysis (STELA) was performed 
as previously described.24 Telomerase activity was assessed using the TeloTAGGG 
telomerase PCR enzyme-linked immunosorbent assay (Roche, Sussex, UK). Replicative 
senescence was evaluated using β-galactosidase staining (Cell Signaling Technology, 
Beverly, MA). Details are in supplemental methods. 
 
IGH sequencing 
IGH sequencing was performed as described in supplemental methods.25 
 
SNP array analysis, whole exome sequencing and RNA-seq 
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Single-nucleotide polymorphism (SNP) array analysis and whole exome sequencing 
(WES) was performed on CLL cells, with isolated granulocyte26 or T-cell fraction as germline 
control. There was no detectable VH rearrangement in the germline fractions (supplemental 
Figure 1). Details of sample preparation, bioinformatics analysis and result validation are 
provided in supplemental methods. Raw WES and RNA-seq data is available in the NCBI 
SRA (Bioproject ID: PRJNA535508; URL: https://www.ncbi.nlm.nih.gov/sra/PRJNA535508). 
 
Results 
Spontaneous disease regression occurs in <2% of patients with CLL and is seen 
exclusively in tumors with mutated IGHV 
We identified 20 individuals who fulfilled the criteria for spontaneous CLL regression, 
a. prevalence of 1.4%, which approximates well with reported frequencies.7,8 Eleven subjects 
underwent complete spontaneous regression (CLL01–11) and 6 partial regression (CLL12–
17). In 2 individuals, onset of CLL regression predated the diagnosis of a second malignancy 
by ≤5 years (CLL18–19). In addition, one patient (CLL20) exhibited complete CLL regression 
for 14 years, which subsequently relapsed (Figure 1; Table 1). 
Patients were followed for a median of 15.2 years (range 3.6–30). Among complete 
regressors, CLL regression occurred over a median of 8.6 years (range 5.3–26). At the time 
of study, lymphocytosis and CLL-related clinical features had been absent for a median of 
2.7 years (range 0.9–12) and consistent with the significantly reduced tumor load, T-cell and 
NK numbers resembled normal levels (Table 2). There was no association between onset of 
regression and initiation of medication for non-CLL related ailments for any patient (Table 1). 
None of the patients were taking non-prescriptive medication known to influence CLL 
course, immediately preceding or coinciding with the onset of CLL regression, nor were they 
frequent green tea consumers. However, the potential contribution of other lifestyle factors, 
holistic or dietary, to regression cannot be discounted. All subjects except one (CLL07) were 
alive at the time of analysis. Importantly, a residual B-lymphocyte population with a CLL 
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phenotype was identifiable by flow cytometry in all the regression samples accounting for a 
median of 92.5% of total B-cells (range 71.6–99.8%; Figure 2A; Table 2).27 
The sequence of the clonal IGHV rearrangement was determined in 19 tumors and 
found to be IGHV-mutated (M-CLL) in all instances (Table 2). A range of IGHV usage was 
observed, including IGHV3 in 12 cases, IGHV4 in 5 cases, and a single case each of IGHV1 
and IGHV2. None exhibited stereotyped BCR usage. 
 
Spontaneous regressed CLL tumors have undergone substantial cell division but 
gradually acquired a low proliferative phenotype 
We analyzed the phenotypic features of the residual CLL clone in spontaneously 
regressed (n=17), indolent (n=54) and progressive (n=40) tumors. We also examined for 
phenotypic changes occurring during spontaneous regression by comparing paired 
diagnostic and regression samples (n=5). The relative accumulation or regression of a tumor 
reflects the balance between cellular proliferation and apoptosis.13,28 We therefore focused 
initially on the proliferative activity of the CLL clone. Spontaneously regressed CLLs 
contained significantly fewer Ki-67-expressing tumor cells (<1%) than either the indolent 
(median 2.5%; P≤0.05) or progressive (median 5%, P≤0.0001) cohorts, indicating a very low 
level of clonal proliferation (Figure 2B). CLL cells that have recently exited proliferation 
centers and stopped receiving proliferation stimuli have low CXCR4 levels, which rapidly 
recover in the circulation.29-31 Consistent with 3.46-fold lower Ki-67 expression, we found 
significantly higher (1.12-fold; P≤0.05) CXCR4 positivity on the CLL cells in spontaneously 
regressed compared to indolent cases (Figure 2C, supplemental Figure 2). In contrast, no 
significant differences were observed in the surface expression of CXCR5, CCR6 and CCR7 
(supplemental Figure 3). 
To investigate the proliferation history of spontaneously regressed CLLs, we 
compared Ki-67 expression from paired diagnosis and regression samples. Ki-67 expression 
significantly reduced from diagnosis in all 5 patients with concomitant increased surface 
CXCR4 in 3 cases, suggesting the possibility of a lower proliferation rate during regression 
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(Figure 2D). Additionally, the mean telomere length of spontaneously regressed CLL was 
found to be comparable to that of non-regressing indolent CLL and was generally <5 kb 
(Figure 2E), suggesting previous proliferation consistent with prior diagnosis of bona-fide 
CLL.24,32 The clonal composition of the tumor was also assessed by IGH sequencing and 
revealed a single clonal population in each case (Table 2). This remained stable between 
diagnosis and regression, as evidenced by identical IGHV-D-J sequence and similar 
telomere length distribution (supplemental Figure 4). Taken together, our results 
demonstrate that spontaneously regressed CLL tumors comprise clones that have 
previously undergone substantial cell division but have subsequently acquired a phenotype 
of low proliferation. 
 
CLL tumors undergoing spontaneous regression display weak BCR signaling 
responses but retain high levels of Bcl-2 
 Clonal attrition is likely to occur when the rate of CLL cell death exceeds that of CLL 
proliferation. Given the dominant role of positive BCR signaling in driving CLL proliferation, 
we asked whether CLL regression might reflect an attenuation of BCR signaling responses. 
All spontaneously regressed tumors were ZAP-70 negative (supplemental Figure 5). We 
analyzed BCR levels and signaling responses in 14 sIgM/sIgD+ spontaneously regressed 
tumors (Figure 3). Anti-IgM mediated responses were lower in indolent M-CLL than in IGHV-
unmutated (UM)-CLL, consistent with previous studies.33-36 However, responses were further 
reduced to undetectable levels in spontaneously regressed CLL (Figure 3B). In contrast, 
substantial IgD responses were retained, although they appeared lower in spontaneously 
regressed CLL compared to indolent M-CLL and UM-CLL (Figure 3C). Indeed, IgD signaling 
accounted for almost all residual signaling upon combined IgM/IgD stimulation in 
spontaneously regressed CLL (Figure3D), with reduced IgM signaling being associated with 
low sIgM expression (Figure 3E-F). All regressed tumors expressed similar sIgM levels to M-
indolent tumors which were lower than UM-indolent CLL (Figure 3E-F). Class switch 
recombination, evident by IgG expression was responsible for the negligible sIgM expression 
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only in a single case (CLL19; data not shown). Thus, the sIgM levels potentially suggest an 
anergic state for the majority of regression cases. Furthermore, comparison of sequential 
spontaneous regression samples revealed 5.01-fold increased CXCR4 and significant 
(P≤0.005) 4.61-fold reduced surface immunoglobulin expression (Figure 2D & 3G), 
suggesting reduced antigen engagement within proliferation centers and positive BCR 
signaling over time, consistent with development of a more quiescent state, potentially 
anergy.35,37 Corroborating these findings, spontaneously regressed CLL exhibited other 
anergic features such as 2-fold higher levels of basal Erk phosphorylation (pERK) than 
healthy B-cells (Figure 4A).38 Also basal pErk38 and B-cell inhibitory receptor LAIR139 levels 
were significantly elevated in regressed CLL compared to indolent M-CLL and UM-CLL 
(P≤0.05), whilst basal Akt phosphorylation was similar (Figure 4A-B). 
 CLL proliferation is dependent on the migration of CLL cells from the peripheral blood 
to the lymph nodes. We evaluated CD49d,40,41 CD62L,42 CD38,41 and ROR143expression, 
molecules important for migration. While no significant difference was observed in ROR1, 
CD38 or CD62L levels, surface CD49d expression was significantly lower between 
spontaneously regressed CLL and indolent tumors, being expressed on <2% of tumor cells 
in most cases (Figure 4C-F, supplemental Figure 2). Concurrent with the attenuation of BCR 
signaling during regression, regressed samples exhibited reduced CD38 (2.44-fold) and 
CD49d (6.93-fold) expression from diagnosis but only in cases with diagnostic expression on 
>5% CLL cells (Figure 4G). As CD49d was the only downregulated chemokine receptor, 
reduced CD49d-mediated trafficking may contribute to CLL regression. 
We next assessed the expression of apoptosis-related proteins in CLL cells. Relative 
to indolent CLL, spontaneously regressing CLL displayed significantly higher FasR 
expression at both mRNA (logFC 0.98, p<0.001) and protein level (Figure 4H, supplemental 
Figure 2), implicating a potential role of the extrinsic apoptotic pathway in spontaneous 
regression. In contrast, comparable levels of the anti-apoptotic proteins Bcl-2 and Mcl-1 was 
seen in spontaneously regressed and indolent tumors (Figure 4I-J). Spontaneously 
regressed CLL continue to express Bcl-2 (Figure 4I), which could potentially contribute to the 
11 
 
 
 
persistence of residual disease along with the concurrent upregulation of chemokines such 
as IL-8/CXCL8 and CXCL2 (Table 3).44-46 
 We hypothesized that the very low rate of proliferation in spontaneously regressed 
CLL clones could also be due to replicative senescence secondary to telomere erosion. To 
investigate this, we measured telomerase activity and beta-galactosidase expression, a 
marker of replicative senescence, within tumor cells. However, telomerase activity was 
higher in spontaneously regressed CLL tumors relative to non-regressing tumors and no 
evidence of beta-galactosidase staining was observed (supplemental Figure 6). As such 
there is no evidence to support replicative senescence as an explanation for decreased CLL 
proliferation during spontaneous regression. 
 Taken together, these results indicate that reduced BCR signaling, coupled with 
potentially curtailed migration to proliferation centers leads to a very low proliferation rate in 
spontaneously regressed tumors. Consistent with a low metabolic, quiescent state, RNA-seq 
analysis of 15 spontaneously regressed CLL tumors demonstrated downregulation of 
pathways involved in RNA metabolism, mRNA translation, protein biosynthesis and oxidative 
phosphorylation compared to age-matched indolent M-CLL (n=17) (Figure 5A-B; 
supplemental Table 4). Furthermore, MYC; an important gene promoting survival and 
proliferation33 was one of the top 5 down-regulated genes in regressors and was associated 
with reduced Myc target gene expression (Figure 5C). Upon both principal component 
analysis (PCA) and multi-dimensional unsupervised hierarchical clustering analysis of the 
entire RNA-seq dataset which also included age-matched progressive M-CLL, UM-CLL and 
healthy controls, spontaneously regressed CLL segregated into a cluster that overlapped 
with the indolent M-CLL cluster (Figure 5D-E). This is consistent with spontaneously 
regressed CLL having a transcriptomic profile that bears the closest resemblance to indolent 
M-CLL. Together, this data potentially indicates that that prior to regression, an indolent 
genomic state is maintained which may render susceptibility to regression following an 
alteration of microenvironmental stimulation. 
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Spontaneous CLL regression occurs in the context of low genomic complexity and 
intraclonal equilibrium 
 The genomic landscape of individual CLL clones is believed to be a major 
determinant of biological behavior.16,17 Analyses of spontaneously regressed CLL tumors at 
various timepoints (n=27) identified 12-57 somatic SNV per sample (supplemental Table 5). 
Furthermore, at the point of maximal spontaneous regression, validated variants of potential 
functional significance (n=18), revealed a pattern of low mutational burden and an absence 
of genomic complexity among spontaneously regressed CLL, with a median of 1 somatic 
copy number variation (CNV, range 0-3) and 2 single nucleotide variations (SNV, range 0-5) 
per case (Figure 6A; Table 4). The most frequent CNV, del(13q14), was present in 11 
tumors (61%), and was clonal in most cases, consistent with it being an early genomic event 
and a likely driver of the initial proliferative phase before regression onset. Mutations 
involving known CLL drivers were seen in 4 cases (22%), a subclonal HIST1H1B mutation in 
one case, and clonal or subclonal TP53 mutations in 3 cases (Figure 6A). All 3 TP53 
alterations were reported missense variants, considered to be damaging by both Polyphen 
and SIFT in silico prediction tools. Variant allelic frequencies (VAFs) ranged from 11.83-
100%. The alteration TP53_g13804G>A has been reported multiple times in CLL, while the 
rest of alterations have been reported in other malignancies (COSMIC 
(http://cancer.sanger.ac.uk/cosmic). Only one (CLL13) occurred concurrently with 17p 
deletion (supplemental Table 6). 
 To determine the pattern of subclonal dynamics during spontaneous CLL regression, 
we analyzed genomic data from sequential diagnostic and regression samples (n=5), 
including 2 complete regression subjects (CLL05, CLL06). Intraclonal equilibrium was a 
predominant feature at the point of regression in 4 subjects, indicated by similar subclonal 
representation across sequential timepoints and no major clonal selection or evolution 
(Figure 6B-C). A degree of clonal evolution involving 3 genes was evident in a single CLL 
(Figure 6D). These observations indicate that in similarity to MBL,47 clonal expansion of 
spontaneously regressed CLL is absent, even in cases harboring driver mutations. This is 
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consistent with the notion that mutational burden alone is insufficient to drive malignancy and 
that sustained clonal expansion requires an interplay between mutational burden, potential 
genomic instability and microenvironmental signals. To investigate this, we revisited our 
RNA-seq dataset. In addition to downregulation of metabolic and proliferative processes, 
several genes involved in DNA repair and telomere maintenance were upregulated in 
spontaneously regressing CLL compared to M-indolent CLL (Table 5). The upregulation of 
the DNA repair genes was confirmed by qPCR (supplemental Figure 7). Notwithstanding the 
presence of genomic aberrations, these features may potentially contribute to the absence of 
genome instability in spontaneously regressing CLL. 
 Tumor immunity represents another mechanism that could suppress CLL 
proliferation in spontaneously regressing disease. CLL regression was accompanied by 
significantly reduced PD-1, LAG3 and CD160 expression on CD8+ T-cells compared to 
indolent cases (P≤0.05), whilst CD244 levels were unchanged (Figure 7A, supplemental 
Figure 2). Furthermore, PD-1 levels decreased from diagnosis on both CD4+ (2-fold) and 
CD8+ (3-fold) T-cells (Figure 7B). T-cell proliferation also significantly (P≤0.05) increased in 
comparison to their respective diagnostic timepoint and indolent CLL (Figure 7C). This 
indicates reversal of T-cell exhaustion possibly due to reduced tumour burden, which may 
result in improved cytotoxicity against CLL cells.21 Furthermore, established CLL is 
associated with impaired immune function including elevated numbers of T- and NK-cells,19-
22 and regression was associated with normalization of T-cell and NK-cell number (Table 2, 
supplemental Figure 8). However, T-cell subset distribution was not significantly altered in 
spontaneously regressed CLL compared to indolent CLL, and CD4:CD8 inversion persisted 
in some cases. 
 
Enhanced co-stimulation can overcome inhibition of BCR signaling in vitro and 
disease acceleration may be driven by clonal evolution 
 To determine the clinical significance of the residual disease that remains after 
spontaneous CLL regression, we examined whether the quiescent state of BCR 
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unresponsiveness in spontaneously regressed CLL could be reversed. We compared BCR 
responses with and without CD40L and IL-4 co-culture as this has previously been shown to 
reverse clonal anergy.48,49 Provision of co-stimulation with CD40L/IL-4 resulted in a recovery 
of BCR responses; elevation of pErk 13.76-fold, pAkt 9.38-fold and pSyk 14.31-fold; in 
spontaneously regressed CLL (Figure 7D), indicating that BCR unresponsiveness is 
reversible, and likely due to chronic antigenic stimulation in the absence of tissue IL-4. This 
substantiates the proposition that CLL cells in regression cases were confined to the 
peripheral circulation for prolonged periods. We compared sequential CLL20 samples, a 
case characterized by CLL relapse following complete spontaneous regression. Disease 
relapse coincided with recovery of BCR responses and CLL proliferation (Figure 7E-F). 
Moreover, relapse was accompanied by clonal evolution in which the subclone harboring 
TP53, KLRC1 and RPGR mutations, dominant at the time of spontaneous regression, was 
replaced by another with ATM, MDC1 and PRP21 mutations at relapse (Figure 6C). 
Collectively, these findings demonstrate that CLL cells from cases of spontaneous CLL 
regression remain susceptible to enhanced co-stimulation and this may potentially represent 
one mechanism of disease progression following clonal evolution. 
 
Discussion 
 In this study, we present the largest cohort of spontaneous CLL regression cases 
analyzed to date. To investigate the natural history and biological processes underpinning 
spontaneous CLL regression, these cases underwent extensive characterization. This 
involved sequential timepoints, integration of flow cytometric, functional, transcriptomic and 
genomic analyses, which distinguishes this study from previously published reports. 
Our results support a model in which spontaneously regressed CLL arises from a 
CLL clone that has undergone extensive prior proliferation, but subsequently transitioned to 
a limited proliferative state with hyporesponsiveness to IgM BCR stimulation. The residual 
CLL clone is likely to be concentrated within peripheral blood due to reduced expression of 
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CD49d which mediates adhesion and transendothelial migration, important for CLL cell 
trafficking to proliferation centers. However, it ultimately remains viable because of sustained 
Bcl-2 expression. Clonal quiescence, possibly together with increased DNA repair activity, 
enables maintenance of genome stability and intraclonal equilibrium despite the presence, in 
some cases, of biologically relevant mutations. Such a model highlights the interdependence 
of genetic and microenvironmental factors in determining the clinical course of patients with 
CLL (Figure 7G). We postulate that under conditions of low genomic complexity and genome 
stability, mutations alone, in the absence of BCR signaling and other microenvironmental 
interactions, are insufficient for CLL progression or to sustain disease. Thus, it appears that 
an indolent genomic state is a required background in most CLLs, on which, an alteration of 
microenvironmental/BCR stimulation may lead to regression and conversely, subsequent 
relapse in combination with genetic alterations. Both intrinsic and extrinsic factors are likely 
to contribute to these changes and therefore probably determine the balance between CLL 
quiescence and proliferation. The order of events and the causative factors may be case-
dependent and could depend on unknown environmental factors. 
This model explains the efficacy of BCR signaling inhibitors in producing durable 
remissions in the frontline setting, where genomic complexity is typically low even in the 
presence of genetic alterations such as TP53 mutations.17,18 In these cases, the effect of 
treatment with BCR signaling inhibitors bears resemblance to spontaneous CLL regression. 
In contrast, in relapsed or refractory CLL with high intrinsic levels of genomic complexity and 
instability, BCR signaling inhibition alone may be insufficient in preventing disease relapse 
arising from clonal evolution, and therapeutic strategies targeting both genetic and 
microenvironmental drivers may be required. Our findings also underscore the significance 
of detectable residual CLL following clinical regression, the outcome of which is dependent 
upon the dynamic interplay between factors that promote continued clonal regression and 
others that promote clonal expansion. This lends support to therapeutic strategies aiming at 
complete CLL eradication, particularly in patients with high-risk biological features. 
16 
 
 
 
 Two findings from our study are of particular interest. Firstly, IgM BCR signaling 
promotes CLL survival and growth,33 and hence its reduction to unmeasurable levels in 
spontaneously regressing cases suggests a quiescent, possibly anergic state that may lead 
irreversibly to cell death. Interestingly, although measurable signals remained, sIgD 
expression and IgD signaling were also reduced in the residual circulating tumor cells from 
spontaneously regressed CLL patients. While the significance of these changes remains to 
be determined, a similar reduction of sIgD has been observed in circulating CLL cells of 
patients receiving ibrutinib therapy that were unable to return to their protective niche within 
lymph nodes. In these cells, the reduced sIgD levels and IgD signaling capacity were likely 
consequent to ongoing autophagy, possibly reflecting an ultimate attempt of the CLL cells to 
survive.50 Secondly, CLL cells are thought to be resistant to Fas-mediated apoptosis,51,52 in 
part through overexpression of TOSO which inhibits procaspase 8 activation.53 The 
significance of high FasR expression in spontaneously regressing CLL is therefore intriguing. 
We did not find a difference in TOSO expression between spontaneously regressed and 
indolent M-CLL from our RNA-seq analysis. However, there remains a possibility that 
spontaneously regressing CLL could have an intrinsic sensitivity to Fas-mediated apoptosis. 
Alternatively, absent IgM signaling may potentially contribute to an increased sensitivity, and 
future studies will need to clarify this. 
Our study identified multiple determinants of spontaneous clonal regression, some of 
which are intrinsic to the CLL clone (e.g. genetics), whereas others appear to be acquired 
(e.g. BCR unresponsiveness). Important questions remain as to how the acquired features 
are developed, and why some CLL tumors, but not others, develop these. One possibility 
relates to the divergent outcome of different BCR-antigen interactions, some of which may 
produce sustained responses, while others may elicit responses that decline over time with 
repeated interactions.54 Another possibility may reflect potential differences in 
immunogenicity, with more immunogenic tumors eliciting stronger T-cell responses that 
result in clonal attrition. Although our preliminary investigation did not reveal significant 
differences in the expression of T-cell co-stimulatory molecules such as CD80, CD86 and 
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CD40 between regressing and non-regressing CLL, further studies are required to explore 
these hypotheses. 
Finally, complete and partial spontaneous regression cases displayed similar 
biological features. This suggests that partial regression cases may represent an earlier 
stage of regression, and with time, complete remission could become apparent. In 
conclusion, our study into the biological basis of spontaneous regression provides a unique 
perspective on the processes underpinning CLL pathogenesis, with treatment implications. 
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Table 1 
 
 
Diagnosis 
Sex 
ALC (x10
9
/L) 
Medical history and  
co-morbidities 
Second malignancy 
Non-CLL related 
drug history 
Year Age Peak Current Site Diagnosis 
Complete spontaneous regression   
CLL01 2005 58 M 9.0 3.2 
Osteoarthritis, hypertension, 
hypercholesterolemia 
Prostate 2014 
Atorvastatin, amlodipine 
(discontinued) 
CLL02 2001 52 M 29.5 3.3 Hypertension, diabetes mellitus - - 
Metformin, ramipril, 
bendroflumethiazide, 
doxazosin, verapamil 
CLL03 1996 66 M 32.7 1.5 
Ischemic heart disease, peripheral 
vascular disease, diabetes mellitus, 
bronchiectasis (since 2010), 
hypertension 
- - 
Alfuzosin, aspirin, 
bendroflumethiazide, 
doxazosin, felodipine, 
lisinopril, simvastatin 
CLL04 1994 58 M 10.5 1.7 
Hypertension, benign prostatic 
hypertrophy, previous 
neurofibroma, osteoarthritis 
- - 
Finasteride, amlodipine, 
ibersartan 
CLL05 2000 56 M 25.7 2.6 
Previous rectal polyp (non-
malignant), diabetes mellitus 
- - Metformin 
CLL06 1997 61 M 27.4 3.5 Diabetes mellitus, hypertension - - Metformin, furosemide 
CLL07 2002 83 M 23.2 3.6 
Hypothyroidism, diabetes mellitus, 
hypertension, benign prostatic 
hypertrophy 
Skin 
(SCC) 
2010 
Aspirin, linagliptin, tamsulosin, 
levothyroxine 
CLL08 2002 72 F 6.7 2.4 
Atrial fibrillation, diverticulosis, 
hypertension, hyperthyroidism, 
cholecystitis (in 2014) 
- - Bisoprolol 
CLL09 1990 46 M 20.2 3.1 
Hypertension, 
hypercholesterolemia 
- - Ramipril, simvastatin 
CLL10 2008 70 M 13.8 3.2 
Hypertension, abdominal aortic 
aneurysm, previous TIA, 
hypercholesterolemia 
- - 
Simvastatin, aspirin, 
lansoprazole, indapamide 
CLL11 2007 75 M 14.5 1.2 Atrial fibrillation, gout 
Skin 
(SCC) 
2013 
Warfarin, bisoprolol, 
lansoprazole, febuxostat, 
donepezil 
Partial spontaneous regression   
CLL12 2000 66 M 40.6 5.6 Previous iron deficiency anemia 
Skin 
(BCC) 
2010 
Omeprazole, temazepam, 
aspirin 
CLL13 2013 73 M 161.0 11.3 Abdominal aortic aneurysm, COPD - - 
Tiotropium and salbutamol 
inhalers 
CLL14 2002 73 F 44.5 8.5 
Ischemic heart disease, 
osteoarthritis, hypertension, 
hypercholesterolemia 
- - 
Aspirin, ramipril, furosemide, 
ropinirole, levetiracetam 
CLL15 2004 61 M 25.9 5.5 
Diabetes mellitus, hypertension, 
hypercholesterolemia   
Simvastatin, doxazosin 
CLL16 2007 36 F 19.6 7.0 Eczema, mild depression - - Nil 
CLL17 2009 81 M 42.4 16.9 
Lewy body dementia, previous 
ischemic heart disease, depression 
- - 
Bumetanide, citalopram, 
donepezil 
Spontaneous regression occurring prior to a second malignancy  
CLL18 2008 60 M 50.2 3.0 Diabetes mellitus, hypertension Prostate 2010 
Aspirin, enalapril, metformin, 
pioglitazone, simvastatin, 
tamsulosin 
CLL19 1987 55 M 78.0 7.7 Diverticulosis, COPD, gout Lung 2010 
Carbocisteine, tamsulosin, 
tiotropium/fluticasone/ 
salmeterol inhalers 
Relapsed spontaneous regression   
CLL20 1993 38 M 52.4 20.0 
Hypercholesterolemia, asthma, 
previous hip replacement 
- - 
Simvastatin, 
salbutamol/formoterol inhalers 
 
Clinical features of subjects with spontaneous CLL regression. ALC, absolute lymphocyte count; TIA, 
transient ischemic attack; COPD, chronic obstructive pulmonary disease; SCC, squamous cell carcinoma; 
BCC, basal cell carcinoma. 
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Table 2 
 
 B-cell 
count 
x10
9
/L 
CLL 
count 
x10
9
/L 
% CLL 
cells of 
B-cells 
% CLL 
cells of 
lympho- 
cytes 
IGH gene usage IGHV % 
homology 
to germline 
T-cell 
count 
x10
9
/L 
CD4+ T-
cell count 
x10
9
/L 
CD8+ T-
cell count 
x10
9
/L 
NK-cell 
count 
x10
9
/L 
 
VH DH JH 
CLL01 1.0 0.9 92.0 28.8 3-30 4-17 4 95.5 1.9 1.2 0.7 0.3 
CLL02 2.1 2.1 99.0 63.6 3-53 2-21 4 93.7 1.0 0.6 0.4 0.2 
CLL03 0.4 0.4 91.6 23.8 1-69 5-12 3 91.7 0.8 0.4 0.4 0.3 
CLL04 0.5 0.5 91.5 28.0 3-48 5-18 1 95.5 1.0 0.7 0.3 0.2 
CLL05 1.4 1.0 71.6 38.5 2-5 2-15 4 96.3 1.1 0.5 0.4 0.1 
CLL06 1.7 1.7 98.8 48.0 4-34 6-13 4 87.9 1.7 0.6 1.0 0.1 
CLL07 2.2 2.2 98.0 59.9 3-23 6-19 3 93.1 1.2 0.7 0.5 0.2 
CLL08 - - 86.1 - 3-15 1-1 3 89.1 - - - - 
CLL09 2.0 1.8 92.2 58.0 4-39 2-8 5 91.8 0.7 0.5 0.2 0.4 
CLL10 1.3 1.2 92.5 37.6 3-13 3-16 6 92.6 1.8 1.0 0.7 0.1 
CLL11 0.7 0.7 98.3 57.3 4-4 3-22 4 94.8 0.4 0.3 0.2 0.1 
CLL12 1.6 1.2 75.0 21.4 3-30 3-10 4 91.7 3.9 1.0 2.7 0.1 
CLL13 5.3 5.3 99.8 46.8 3-74 2-21 5 88.9 4.4 3.6 0.6 1.6 
CLL14 6.6 6.5 98.2 76.2 3-23 6-6 2 89.9 1.6 0.8 0.6 0.3 
CLL15 3.4 3.4 99.2 61.3 3-30 1-1 3 97.6 1.8 0.9 0.9 0.3 
CLL16 6.1 5.9 96.4 84.0 3-23 4-17 5 92.7 0.6 0.3 0.3 0.3 
CLL18 1.9 1.8 92.4 58.5 3-23 6-19 5 93.1 0.9 0.4 0.4 0.3 
CLL19 6.7 6.2 92.0 80.0 4-34 5-18 6 95.1 0.7 0.4 0.3 0.3 
CLL20 - - - - 4-34 6-19 3 94.7 - - - - 
 
Lymphocyte count and characteristics of the IGH gene in subjects with spontaneous CLL regression. 
B-cell, CD4+ T-cell, CD8+ T-cell and NK-cell count were derived from the ALC taking into consideration the 
proportion of lymphocytes that were CD19+, CD3+CD4+, CD3+CD8+ and CD16+ CD3-neg CD4-neg 
respectively. The CLL count was derived from the B-cell count taking into account of the proportion of CLL 
cells in the B-lymphocyte population, determined using the methodology illustrated in Figure 2A. IGH 
sequencing was performed on DNA from sorted CLL cells using IGHV leader and IGHJ consensus primers. 
Gene usage and % homology to the germline IGHV sequence was determined using the international 
immunogenetics information (IGMT) platform. 
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Table 3 
 
Gene name logFC P-value Function 
CXCL8 3.20 0.001 Chemokine 
CXCL7 2.72 0.001 Chemokine 
CXCL2 2.66 0.002 Chemokine 
CXCL4 2.52 0.002 Chemokine 
CCR1 2.03 <0.001 Chemokine receptor 
CXCL4L1 1.74 0.001 Chemokine 
CXCL5 1.34 0.003 Chemokine 
 
Differentially expressed genes encoding chemokines and chemokine receptors in spontaneously 
regressed CLL compared with indolent M-CLL. Transcriptome sequencing data from sorted CD19+CD5+ 
CLL cells was analyzed comparing spontaneously regressed CLL (n=15) against indolent M-CLL (n=17). 
Positive logFC values identify genes that are upregulated in spontaneously regressed CLL.  
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Table 4 
 
 
CNV 
CLL01 8q24.13 del (x1; TRIB1; NSMCE2); 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
CLL02 10q26.3 gain (x3); 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
CLL03 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7) 
CLL04 2q13 del (x1); 3p24.2-p24.3 gain (x3; NKIRAS1) 
CLL05 13q14.2- q14.3 del (x0;  miR15a/16-1, DLEU7) 
CLL06 3q23 gain (x3); 13q14.2-q14.3 del (x0; miR15a/16-1, DLEU7; RNASEH2B) 
CLL07 3q11.1-q11.2 gain  (x3) ; 4q28.3 gain (x3); 11p13-p14.1 gain (x3; WT1)   
CLL08 No detectable CNV 
CLL09 7q11.23 del (x1) 
CLL10 7q31.33-q32.1 gain (x3; POT1); 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
CLL11 13q14.2-q14.3 del (x1; miR15a/16-1, DLEU7) 
CLL12 2p16.1 del (x1) 
CLL13 8p del (x1; TNFRSF10A); 13q14.2-q14.3 del  (x1; miR15a/16-1, DLEU7); 17p del (x1; TP53)  
CLL15 
12q21.2-q31 gain (x3; PAWR); 13q14.2-q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B);  
16q11.2-q12.1 gain (x3) 
CLL16 13q14.2-q14.3 del (x1; miR15a/16-1, RNASEH2B; RB1) 
CLL18 6p22.3 gain (x3) 
CLL19 7p12.1 gain (x3) 
CLL20 13q14.2-q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
 
Copy number variations (CNV) in 18 spontaneously regressed CLL tumors. Shown in brackets following 
each CNV are the copy number within the cytoband, followed by any genes within the cytoband that could 
potentially be functionally significant. Highlighted in bold are CNVs that have not been previously reported in 
major CLL genomic studies. Data derived from the sorted CD19+CD5+ CLL population. 
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Table 5 
 
Gene name logFC P-value Function 
SETMAR 0.81 0.002 Component of the telomerase complex essential for telomere maintenance 
FANCL 0.71 0.002 Mediates monoubiquitination of FANCD2, an important step in DNA damage response 
MLH3 0.68 <0.001 Important component of DNA mismatch repair 
RAD50 0.67 <0.001 
Essential mediator of double-strand break repair, DNA recombination and  
telomere maintenance 
ALKBH8 0.58 0.001 tRNA nucleoside involved in DNA damage response 
POLA1 0.58 0.001 Regulates the initiation of DNA replication 
PRIM2 0.57 0.001 
Synthesizes the small RNA primers used to generate Okazaki fragments in the lagging 
strand during DNA replication 
ATM 0.56 0.002 
Essential mediator in double-strand break repair, DNA recombination and  
apoptosis in response to genotoxic stress 
MMS22L 0.52 0.003 Involved in the repair of stalled or collapsed replication forks by recombination 
ATRX 0.48 0.002 Involved in gene regulation and chromatin modeling during DNA replication 
POT1 0.44 0.003 Component of the telomerase complex essential for telomere maintenance 
APEX1 -0.68 <0.001 Involved in cellular response to oxidative stress 
 
Differentially expressed genes involved in DNA repair and genome stability in spontaneously 
regressed CLL compared with indolent M-CLL. Transcriptome sequencing data derived from sorted 
CD19+CD5+ CLL cells was analyzed comparing spontaneously regressed CLL (n=15) against indolent M-
CLL (n=17). Positive logFC values identify genes that are upregulated in spontaneously regressed CLL, 
whereas negative logFC values identify genes that are downregulated. 
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Figure legends 
Figure 1. Clinical features of 20 spontaneous CLL regression cases. Spontaneous CLL 
regression cases were categorized into 4 groups: complete spontaneous regression (red 
curves), partial spontaneous regression (blue curves), spontaneous regression occurring 
prior to a second malignancy (green curves) and relapsed spontaneous regression (purple 
curves). The absolute lymphocyte count (ALC) for each patient is plotted against the time 
elapsed from the date of diagnosis. Clinical features are annotated, and the time of 
peripheral blood sampling is displayed at the bottom each chart. T0 represents the 
diagnostic timepoint, whereas T1 and T2 represent the regression timepoints, except in 
CLL20 where T2 represents the relapse timepoint. LN, lymphadenopathy (the measurement 
displayed corresponds to the size of the largest palpable node); Tx, treatment 
 
Figure 2. Spontaneously regressed CLL tumors are composed of a non-proliferating 
CLL clone that has previously undergone substantial cell division. (A) A CD19 gate 
was applied to the PBMC cells to select for CD19+ B-lymphocytes (not shown). The CLL 
population (shown in red) could be distinguished from the non-malignant B-lymphocyte 
population (shown in green) by their immunophenotype, as demonstrated by the example of 
CLL05. CLL cells exhibit high CD5 and CD43 but low CD20, CD79b and CD81 expression, 
whereas non-malignant B-lymphocytes exhibit high CD20, CD79b and/or CD81 expression. 
This methodology was used to determine the proportion of CLL cells within the B-lymphocyte 
population, the results of which are displayed in Table 2. (B-C) The gated CLL population of 
PBMCs was analyzed for the expression of Ki-67 and CXCR4. For each comparison, 17 
spontaneous regression cases (REG) from the regression timepoint (T1) were compared 
against 54 indolent (INDOL) and 40 progressive (PROG) cases. Complete and partial 
spontaneous regression cases are represented by red and blue dots respectively as shown. 
Statistical significance was determined using one-way ANOVA with Bonferroni post-hoc 
analysis for cohort comparison and two-tailed paired student t-test for timepoint comparison. 
Statistical significance is indicated by *p<0.05, **p<0.01 and ****p<0.0001; ns denotes 
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comparisons that are not statistically significant. (D) Expression of Ki-67 and CXCR4 was 
compared between two sequential timepoints in individual spontaneous regression cases. 
T0 and T1 represent the diagnostic and the regression timepoint respectively. Each colored 
line represents a specific case as indicated. (E) XpYp STELA was performed on sorted 
CD19+CD5+ CLLs to assess the telomere length of chromosomes Xp and Yp of CLL cells. 
Left panel: The telomere length distribution of the CD19+CD5+ sorted CLL Xp and Yp 
chromosomes in each case is shown. Right panel: The mean CLL XpYp telomere length 
was compared between spontaneously regressed and indolent cases. Complete and partial 
spontaneous regression cases are represented by red and blue dots respectively as shown. 
Statistical significance was determined using Student’s T test; n.s. denotes comparisons that 
are not statistically significant. 
 
Figure 3. Spontaneously regressed CLL tumors are characterized by weak BCR 
signaling response and sIgM expression. FACS analysis of the gated CLL fraction of 
PBMCs. BCR signaling responses to IgM and IgD stimulation was assessed by phosphoflow 
using fresh blood samples. Cells were stimulated with anti-human IgM and/or IgD F(ab’)2 
antibodies prior to acquisition on a flow cytometer. Combined IgM and IgD stimulation 
reflects BCR stimulation in vivo, whereas separate IgM and IgD stimulation allows dissection 
of the relative contribution of IgM and IgD responses to the overall BCR signaling response 
in each comparator group. (A) Left panel: The CD19+ CD5+ CLL population (shown in red) 
was gated and analyzed for the phosphorylation of Syk, Erk and Akt, with the CD19− CD5+ 
T-cell population (shown in blue) being used as the internal negative control. The positive vs 
negative gate for p-Syk, p-Erk and p-Akt was set such that 99% of unstimulated cells would 
fall within the negative gate. Right panel: Example histograms showing results of a typical 
indolent M-CLL case and a spontaneous regression case with combined IgM/IgD 
stimulation. Phosphoprotein response to (B) IgM, (C) IgD or (D) combined IgM and IgD BCR 
stimulation, as well as CLL cell surface (E) IgM (sIgM) and (F) IgD (sIgD) expression. 
Spontaneous regression cases (REG; n=14) from the regression timepoint (T1) were 
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compared against indolent (INDOL) M-CLL (n=35) and UM-CLL (n=4) cases. Complete and 
partial spontaneous regression cases are represented by red and blue dots respectively as 
shown. (G) Expression of sIgM and sIgD was compared between two sequential timepoints 
in individual spontaneous regression cases. T0 and T1 represent the diagnostic and the 
regression timepoint respectively. Each colored line represents a specific case as indicated. 
Statistical significance was determined using one-way ANOVA with Bonferroni post-hoc 
analysis for cohort comparison and two-tailed paired student t-test for timepoint comparison. 
Statistical significance is indicated by *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001; ns 
denotes comparisons that are not statistically significant. 
 
Figure 4. Spontaneously regressed CLL tumors express weak surface CD49d but 
retain high levels of Bcl-2. FACS analysis of the gated CLL population of PBMCs. The 
gated CLL population was analyzed for (A) basal Erk and Akt phosphorylation and (B) cell 
surface LAIR1 expression. Spontaneous regression cases (REG; n=14) from the regression 
timepoint (T1) were compared against indolent (INDOL) M-CLL (n=35) and UM-CLL (n=4) 
cases. Basal Erk and Akt phosphorylation in CLL cells was normalized to B-cells from 3 age-
matched healthy donors, and expressed as fold change compared to these controls. CLL 
expression of (C) ROR1, (D) CD38, (E) CD62L and (F) CD49d on spontaneous regression 
cases (REG, n=17) from the regression timepoint (T1) compared to indolent (INDOL, n=54) 
and progressive (PROG, n=40) cases. (G) Expression of CD49d and CD38 was compared 
between sequential diagnostic (T0) and regression (T1) timepoints in individual spontaneous 
regression cases. The gated CLL population was analyzed for the expression of (H) FasR, 
(I) Bcl-2 and (J) Mcl-1. For all comparisons except Mcl-1, 17 spontaneous regression cases 
(REG) from the regression timepoint (T1) were compared against 54 indolent (INDOL) and 
40 progressive (PROG) CLL cases. For Mcl-1, 11 spontaneous regression cases from the 
regression timepoint (T1) were compared against 20 indolent and 29 progressive cases. In 
(A-F) and (H-J), complete and partial spontaneous regression are represented by red and 
blue dots respectively. Statistical significance is indicated by *p<0.05, **p<0.01, ***p<0.001 
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and ****p<0.0001; ns denotes comparisons that are not statistically significant. In (G), each 
colored line represents a specific case and 5% expression is indicated (- - -). 
 
Figure 5. Spontaneously regressed CLL tumors exhibit a distinct transcriptomic 
profile. RNA-seq was carried out on sorted CD19+CD5+ CLL cells from subjects with 
spontaneous CLL regression (n=15, from the regression timepoint), indolent M-CLL (n=16), 
progressive M-CLL (n=8) and UM-CLL (n=8), or on isolated B-cells from healthy donors 
(n=3). (A) Gene expression profiles of spontaneously regressed tumors were compared 
against that of age-matched indolent M-CLL tumors, by one-way ANOVA with Tukey post-
hoc analysis. Hierarchical clustering analysis demonstrates differential gene expression 
between spontaneously regressed and indolent M-CLL. (B) Gene set enrichment analysis 
showing differential expression of MYC and Myc target genes in spontaneously regressed 
versus indolent M-CLL tumors. (C) Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) analysis showing enrichment of biological processes in spontaneously 
regressed CLL relative to indolent M-CLL. Biological processes that are upregulated in 
spontaneously regressed CLL are indicated in red, whereas those that are downregulated in 
these tumors are indicated in blue. (D) Multidimensional principal component analysis (PCA) 
of all samples by partial least squares discrimination (PLS-DA) showing distinct clustering of 
spontaneous regression cases. (E) Unsupervised hierarchical clustering analysis of all 
samples showing clustering of spontaneous regression cases overlapping with indolent M-
CLL cases. 
 
Figure 6. Genomic landscape of spontaneously regressing CLL tumors. WES data 
initially analysed using standard bioinformatics criteria, subsequently underwent further 
selection to minimise artefacts and focus on variants of potential functional significance. The 
selected variants were predicted to be truncating or frameshift, missense mutations 
predicted to be deleterious, variant allele frequency ≥20% and could be validated by Sanger 
or RNA sequencing. (A) The genomic landscape of 18 spontaneously regressed sorted 
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CD19+CD5+CLL tumors is displayed. The CNV data of each spontaneous regression case 
is combined with their respective SNV data obtained from WES. Different types of genomic 
events are represented by different colors, with the color code displayed adjacent to the 
table. The frequency of each genomic event is represented in the bar chart beneath the 
table. VAF, variant allelic fraction. (B-D) Fish plots of somatic variants in sorted 
CD19+CD5+CLL cells from (B) CLL05, CLL06 and CLL19 showing clonal equilibrium during 
the course of spontaneous regression, (C) CLL20 showing clonal equilibrium followed by 
clonal evolution during CLL relapse after spontaneous regression, and (D) CLL02 showing 
clonal fluctuation during regression. T0, T1 and T2 represent the diagnostic, regression and 
relapse timepoints, respectively. 
 
Figure 7. T-cell phenotypic features of spontaneously regressing tumors, re-activation 
of BCR signaling associated with relapse following spontaneous CLL regression and 
biological processes underpinning spontaneous CLL regression. FACS analysis of the 
gated T-cell population of CLL PBMCs. (A) PD-1, LAG3, CD160, CD244, CTLA4 and Tim3 
expression on CD4+ and CD8+ T-cells in spontaneous regression cases (REG; n=16) from 
the regression timepoint (T1) was compared against indolent cases (INDOL; n=31) and age-
matched healthy controls (CTRL; n=6). (B) PD-1 expression in T-cells was compared 
between the diagnostic (T0) and regression (T1) timepoints in individuals with spontaneous 
CLL regression. (C) Ki-67 expression in T-cells of spontaneous regression cases (CTRL; 
n=16) from the regression timepoint (T1) was compared against indolent cases (INDOL; 
n=31) and age-matched healthy controls (CTRL; n=6) and also between the diagnostic (T0) 
and regression (T1) timepoints in individuals with spontaneous CLL regression. (D) PBMCs 
from spontaneously regressed cases at maximal regression (n=7) were incubated at 37°C 
for 48 hours in the presence and absence of CD40L-expressing fibroblasts and IL-4 (25 
ng/mL), after which the CLL population was analyzed for Erk, Akt and Syk phosphorylation in 
response to combined IgM/IgD BCR stimulation. Expression of (E) Ki-67 and (F) 
phosphoprotein response to combined BCR stimulation of PBMC with anti-human IgM and 
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IgD F(ab’)2 antibodies were compared between the regression (T1) and relapse (T2) 
timepoints of CLL20. (G) Schematic diagram illustrating the key biological processes 
underpinning spontaneous CLL regression (REG) and key differences as compared to non-
regressing indolent (INDOL) and progressive (PROG) CLL. Statistical significance was 
determined using one-way ANOVA with Bonferroni post-hoc analysis between CLL cohorts 
and paired t-test between timepoints or stimulus. Statistical significance is indicated by 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001; ns denotes comparisons that are not 
statistically significant. 
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